Literature DB >> 35100422

Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma.

Renee D Read1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35100422      PMCID： PMC9071275          DOI： 10.1093/neuonc/noac019

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  10 in total

1.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.

Authors:  Krishna P L Bhat; Katrina L Salazar; Veerakumar Balasubramaniyan; Khalida Wani; Lindsey Heathcock; Faith Hollingsworth; Johanna D James; Joy Gumin; Kristin L Diefes; Se Hoon Kim; Alice Turski; Yasaman Azodi; Yuhui Yang; Tiffany Doucette; Howard Colman; Erik P Sulman; Frederick F Lang; Ganesh Rao; Sjef Copray; Brian D Vaillant; Kenneth D Aldape
Journal:  Genes Dev       Date:  2011-12-15       Impact factor: 11.361

2.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

Authors:  Yi Liu-Chittenden; Bo Huang; Joong Sup Shim; Qian Chen; Se-Jin Lee; Robert A Anders; Jun O Liu; Duojia Pan
Journal:  Genes Dev       Date:  2012-06-07       Impact factor: 11.361

3.  YAP/TAZ maintain the proliferative capacity and structural organization of radial glial cells during brain development.

Authors:  Alfonso Lavado; Ruchika Gangwar; Joshua Paré; Shibiao Wan; Yiping Fan; Xinwei Cao
Journal:  Dev Biol       Date:  2021-08-19       Impact factor: 3.582

4.  Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.

Authors:  Anne Marie Barrette; Halle Ronk; Tanvi Joshi; Zarmeen Mussa; Meenakshi Mehrotra; Alexandros Bouras; German Nudelman; Joe Gerald Jesu Raj; Dominique Bozec; William Lam; Jane Houldsworth; Raymund Yong; Elena Zaslavsky; Constantinos G Hadjipanayis; Marc R Birtwistle; Nadejda M Tsankova
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

5.  Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.

Authors:  Jiyong Liang; Lulu Wang; Chao Wang; Jianfeng Shen; Bojin Su; Anantha L Marisetty; Dexing Fang; Cynthia Kassab; Kang Jin Jeong; Wei Zhao; Yiling Lu; Abhinav K Jain; Zhicheng Zhou; Han Liang; Shao-Cong Sun; Changming Lu; Zhi-Xiang Xu; Qinghua Yu; Shan Shao; XiaoHua Chen; Meng Gao; Francois X Claret; Zhiyong Ding; Jian Chen; Pingsheng Chen; Michelle C Barton; Guang Peng; Gordon B Mills; Amy B Heimberger
Journal:  Cancer Immunol Res       Date:  2020-04-07       Impact factor: 11.151

Review 6.  The Hippo Signaling Pathway in Development and Disease.

Authors:  Yonggang Zheng; Duojia Pan
Journal:  Dev Cell       Date:  2019-08-05       Impact factor: 12.270

7.  EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.

Authors:  Minling Gao; Yi Fu; Mingyao Ying; Weiqiang Zhou; Gege Gui; Bachuchu Lal; Yunqing Li; Shuli Xia; Hongkai Ji; Charles G Eberhart; John Laterra
Journal:  Cancer Res       Date:  2021-04-28       Impact factor: 12.701

8.  Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma.

Authors:  Martina Castellan; Alberto Guarnieri; Atsushi Fujimura; Francesca Zanconato; Giusy Battilana; Tito Panciera; Hanna Lucie Sladitschek; Paolo Contessotto; Anna Citron; Andrea Grilli; Oriana Romano; Silvio Bicciato; Matteo Fassan; Elena Porcù; Antonio Rosato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nat Cancer       Date:  2020-12-07

9.  Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma.

Authors:  Jessica Tome-Garcia; Parsa Erfani; German Nudelman; Alexander M Tsankov; Igor Katsyv; Rut Tejero; Martin Walsh; Roland H Friedel; Elena Zaslavsky; Nadejda M Tsankova
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

10.  YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.

Authors:  Krishanthan Vigneswaran; Nathaniel H Boyd; Se-Yeong Oh; Shoeb Lallani; Andrew Boucher; Stewart G Neill; Jeffrey J Olson; Renee D Read
Journal:  Clin Cancer Res       Date:  2020-11-10       Impact factor: 12.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.